6,7-dichloro-2-cyclopentyl-5-hydroxy-indan-1-one | 57509-32-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6,7-dichloro-2-cyclopentyl-5-hydroxy-indan-1-one
• 英文别名: 2-cyclopentyl-5-hydroxy-6,7-dichloro-1-indanone；6,7-Dichloro-2-cyclopentyl-5-hydroxy-2,3-dihydroinden-1-one
• CAS: 57509-32-7
• 化学式: C₁₄H₁₄Cl₂O₂
• 分子量: 285.17
• InChiKey: AZOKCOPZUKSMEY-UHFFFAOYSA-N

物化性质

• 沸点：
  451.5±45.0 °C(Predicted)
• 密度：
  1.427±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7-dichloro-2-cyclopentyl-5-hydroxy-indan-1-one 在 叠氮基三甲基硅烷 、 二正丁基氧化锡 、 potassium carbonate 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 6,7-dichloro-2-cyclopentyl-5-[4-(2H-tetrazol-5-yl)-benzyloxy]-indan-1-one
  参考文献：
  名称：

  Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators

  摘要：

  We have identified and synthesized a series of phenyl-tetrazolyl and 4-thiopyridyl indanones as allosteric potentiators of the metabotropic glutamate receptor 2. Structure activity relationship studies directed toward improving the potency and level of potentiation, as well as PK properties, led to the discovery of 28 (EC50 = 186 nM), which displayed activity in a rodent model for schizophrenia. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.077
• 作为产物：
  描述：

  2,3-二氯茴香醚 在 aluminum (III) chloride 、 盐酸二甲胺 、 溶剂黄146 、 sodium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 55.17h， 生成 6,7-dichloro-2-cyclopentyl-5-hydroxy-indan-1-one
  参考文献：
  名称：

  Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes

  摘要：

  2型糖尿病与胰岛素抵抗、胰岛β细胞胰岛素分泌受损和非酒精性脂肪性肝病有关。组织特异性的SWELL1消融影响了脂肪、骨骼肌和内皮细胞中的胰岛素信号传导，影响了β细胞的胰岛素分泌和血糖控制。在这里，我们展示了在小鼠和人类糖尿病中，脂肪和β细胞中的I_Cl,SWELL和SWELL1蛋白质被降低。通过结合冷冻电镜、分子对接、药物化学和功能研究，我们定义了一种结构活性关系，以合理设计SWELL1通道抑制剂（DCPIB/SN-401）的活性衍生物，这些衍生物结合SWELL1六聚体复合物，通过SWELL1依赖机制恢复SWELL1蛋白质、质膜转运、信号传导、血糖控制和胰岛素分泌。在体内，SN-401恢复小鼠糖尿病的血糖控制，减少肝脏脂肪变性/损伤，改善胰岛素敏感性和胰岛素分泌。这些发现表明，SWELL1通道调节剂改善了2型糖尿病中依赖SWELL1的全身代谢，代表了糖尿病和非酒精性脂肪性肝病的首个一类治疗方法。

  DOI：

  10.1038/s41467-022-28435-0

文献信息

• [1-Hydroxy-5-indanyloxy (or thio)]-alkanoic acids
  申请人：Merck & Co., Inc.

  公开号：US04012524A1

  公开（公告）日：1977-03-15

  [1-Hydroxy-5-indanyloxy (or thio)]alkanoic acids and their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and hypouricemic activity. The acid products are prepared by several synthetic methods.

  揭示了1-羟基-5-茚氧（或硫）烷酸及其盐、酯和酰胺。这些产品在药用上具有双重作用，表现出利尿、排钠和降尿酸活性。这些酸产品可以通过几种合成方法制备。
• [EN] INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] FACTEURS DE POTENTIALISATION D'INDANONE DE RÉCEPTEURS MÉTABOTROPIQUES DE GLUTAMATES
  申请人：MERCK & CO INC

  公开号：WO2006015158A1

  公开（公告）日：2006-02-09

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及一类潜在激活代谢型谷氨酸受体的化合物，包括mGluR2受体，这些化合物在治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病中具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。
• Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
  申请人：Pinkerton B. Anthony

  公开号：US20080096935A1

  公开（公告）日：2008-04-24

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及一种激活型代谢型谷氨酸受体的化合物，包括mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及代谢型谷氨酸受体的疾病中使用这些化合物和组合物。
• Indanone Potentiators of Metabotropic Glutamate Receptors
  申请人：Pinkerton Anthony B.

  公开号：US20080312286A1

  公开（公告）日：2008-12-18

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及增强代谢型谷氨酸受体（包括mGluR2受体）的化合物，用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及代谢型谷氨酸受体的疾病中使用这些化合物和组合物。
• Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor
  作者：Céline Bonnefous、Jean-Michel Vernier、John H. Hutchinson、Michael F. Gardner、Merryl Cramer、Joyce K. James、Blake A. Rowe、Lorrie P. Daggett、Hervé Schaffhauser、Theodore M. Kamenecka

  DOI：10.1016/j.bmcl.2005.06.062

  日期：2005.10

  We have identified and synthesized a series of biphenyl-carboxylic acid indanones as allosteric potentiators of the metabotropic glutamate receptor 2. Structure-activity relationship studies directed toward improving the potency and the brain to plasma ratio of the initial lead led to the discovery of 5 and 23 (EC50 = 111 and 5 nM, respectively). (c) 2005 Elsevier Ltd. All rights reserved.